CytoDyn (CYDY) Gross Profit (2021)

CytoDyn (CYDY) posted Gross Profit of $173000.0 for Q4 2021, up 332.5% on a QoQ basis from $40000.0 in Q3 2021.

CytoDyn (CYDY) Gross Profit (2021) Analysis & Trends

CytoDyn's Gross Profit history runs 1 years deep, the most recent figure standing at $173000.0 for Q4 2021.

  • Quarterly Gross Profit changed N/A year-over-year to $173000.0 in Q4 2021, while the trailing twelve-month figure through May 2022 was $213000.0 (changed N/A YoY) and the FY2022 annual result came in at $213000.0, changed N/A from the prior year.
  • Gross Profit was $173000.0 for Q4 2021 at CytoDyn, up from $40000.0 in the prior quarter.
  • Across five years, Gross Profit topped out at $173000.0 in Q4 2021 and bottomed at $40000.0 in Q3 2021.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 67,072.09 Bn 67,072.09 Bn -
2 Nanobiotix 1,894.61 Bn 1,894.55 Bn -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn -
4 BeOne Medicines 471.64 Bn 466.85 Bn 1.35 Bn
5 Vertex Pharmaceuticals 121.72 Bn 114.47 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 68.28 Bn 59.52 Bn 3.31 Bn
7 Belite Bio 61.40 Bn 61.40 Bn -
8 Argenx Se 56.94 Bn 56.94 Bn 1.18 Bn
9 Revolution Medicines 37.37 Bn 37.37 Bn -
10 CytoDyn 248.66 Mn 248.66 Mn -

Historic Data

Download Data
DateValue
Nov 30, 2021 173,000.00
Nov 30, 2021 173,000.00
Aug 31, 2021 40,000.00
Aug 31, 2021 40,000.00